George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
well said post rec.
Sorry to chirp in on your conversation but I am intrigued by the comment about being 'entitled '.
When we buy shares in Scancell or any company ( other than a placing ) we are buying on the secondary market. Those shares can float through our fingers either making a profit or a loss.
If we hold shares on a particular date when we can vote most of us don't or we just pass to a proxy. Holding shares gives us no special privileges or demands on the company.
We are attached for the ride and that's all.
It's our belief in what the future has in stall that means we either continue to hold / buy more or we sell up.
Chester.
actually Ivy i am not concerned at all by a low SP ... seems that there is always somebody to buy them ... which cancels out your negativity ...
the market has two sides ...
as a constant buyer of Scancell the lower the better ...
at the end of the day .... if the trials come good, all is well .. and i do not think for one second the sp will be 6p
so rather than selling before we engage on the trial journey and the results from the collaboration's at this very low SP like you ......
I am a buyer .............
and every one that sells is selling to a party with the opposite view
and its that what makes the market ..
You are only One side ..
Tick Tock
As you say Bermuda you are totally correct that investors have been reasonably patient and although they may not understand the intricacies or minutiae of all the cutting edge science they certainly do understand the constant delays,the failure to generate the data and external validation that the BoD itself have prioritised and the failure to monetise the assets,update SH on a regular basis and I could go on.
Many SH have been here over 5 years and have only observed a declining SP apart from the odd reverse on decent news.
There is only one person who does not understand why investors are not buying shares here but it really is quite simple if real progress is made and communicated by the BoD people will buy shares and the SP ( dilution excepted) will go up.
If there is no news then people will sell as the SP goes down.
If you have an open mind then these are fairly simple concepts to understand it is only if you have a closed mind that you struggle to understand the facts
I think that is good advice.
Here, I'm attempting to stay as dry as possible today. The birds are chirping in the rain and some of the day lilies have decided that today is the day to open for the first time. Clouds across the loch have lifted to just above the roofs, so I reckon it's time to make a cuppa and put on the extended editions of the Tolkein cycle.
I appreciate Wimbledon is cancelled ... but lets not play the game here
ATB
“yes and you have had them .........“
OK, you have changed your mind - I AM entitled.
So I DON’T need to apply to parliament, my rights are and always have been enshrined in law.
i am sure that would fit inside your valuation of £10 a share LOL
“ what else do you need to know ?“
How much we going to get paid for it.
for instance
Lindy has told us ... yes we have a working T cell cloned from a moditope CD4 via TCR transfection
They have shown you the workings of MAB2811
what else do you need to know ?
as like any collaboration you get the details at the end ... not at the beginning
The directors have duties and responsibilities laid down in law to update the market.
yes and you have had them .........
but you are not satisfied
Inan,
“ Entitled ... ? No you are not ... You gave that Role to the Directors of Scancell who follow strict rules laid down in law to update the market”
Yes I am, as you yourself have stated The directors have duties and responsibilities laid down in law to update the market.
Funny how the same sentence that we agree on brings you to the conclusion “no you’re not” but I conclude “yes I am”.
I suppose we could agree to differ but why should I, you are just plain wrong.
Now, where’s my update?
have the industry ever worked with Homocitrullianted peptides from cancer
No
that is why its a new patent
so we have no comparison other than modi1 to work from , but from that experience we now know that manufacturing a Hydrophobic conjugated peptide ... is difficult ...so we should take that into account when considering time scales
PS we don't know if they need to be hydrophobic
once the process is sorted on the scale up from lab to production .. we should not worry about that again ..
Bermuda
These Two questions relate to Cutting edge
Any progress on MODI2?
Any news on the BioNTech collaboration?
Entitled ... ?
No you are not ... You gave that Role to the Directors of Scancell who follow strict rules laid down in law to update the market
you can only appeal to Parliament . to improve your "entitlement"
but if you approach Dawn Butler you must present in all languages
Inanaco,
'investors that just don't appreciate the cutting edge of Science that we are working in'
Sorry but I just don't buy this idea that somehow shareholders are being unreasonably impatient because they don't understand the science. Scancell are fortunate in that they have many shareholders who have been incredibly patient over the last 5 years. By all means defend the Company by explaining the delays but please don't blame the shareholders.
the point of this is to show that if you have an antigen like moditope that can activate the immune system at such a high level ie bringing in a CD4 that has cytotoxic capability as well as all its other functions what out don't want to do is give the activated T cell High Avidity which really are the target for poor expression of the target epitope on cancer ... this all ties in with anther escape mechanism of cancer antigenic loss
this is why a poor vaccine against cancer has the potential to make the cancer shrink but then enter a growth phase again
""""It is well established that cancer cells typically lose surface antigens following natural or therapy-induced selective pressure and these antigen-loss variants are often the population that causes therapy-resistant relapse"""
its a War .....
Inan,
Sorry, but you don’t conduct clinical trials with science you conduct them with products as in the “great products” that come from “great science”
I DO appreciate the cutting edge science of Scancell
I am as appalled as you at the poor results in cancer treatment despite the billions invested
I agree, Scancell have done a lot with the relatively small funds raised to date.
In order to progress the science and products, far more money will be needed.
As an investor, surely I am entitled to an an update from the company itself rather than the speculation of a fellow investor?
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1808794/
dont read over breakfast ...
now wash your hands...
Superantigens (SAgs) are the most powerful T cell mitogens ever discovered. Concentrations of less than 0·1 pg/ml of a bacterial superantigen are sufficient to stimulate the T lymphocytes in an uncontrolled manner resulting in fever, shock and death
Inanaco - yes the principle of viral vectors sounds simple ie. using viruses to deliver genetic material into human cells but it's so complex. To do list:-
1) Modify the vector to make sure it doesn't infect the host with the original virus.
2) Ensure it will 'infect' only the cells you want it to and not healthy cells
3) Ensure it will dump its genetic load in the correct place
Genetic engineering is another world and I have no intention of trying to understand it at anything other than a very, very basic level.
from great science you get the ability to enter clinical trial ....
Obstacles exist
for instance the FDA ........... now sorted
Modi1 manufacture of the conjugates........ now sorted
hurdle Covid
what cannot be sorted easily ... is investors that just don't appreciate the cutting edge of Science that we are working in
That the industry has spent 100,s of billions over the past 100 years and still people die of cancer
and that Scancell has achieved an awful lot with £30m
however .. Rucks ? list will not be answered here, thus he is allowed to sit and bite finger nails wondering if his £10 target will be reached ...
What might be more interesting...
What’s the revised timetable for the SCIB1 combo trial?
What’s the revised timetable for the SCIB2 trial?
What’s the revised timetable for the MODI1 trial?
Any progress on MODI2?
Any news on the BioNTech collaboration?
Any news on funding?
What’s the revised timetable on getting some “great data”?
What is the revised timetable on “monetising assets”?
Bermuda ... further to the patent discussions and our understanding of the way the TCR is transfected ..
from this text it appears the Viral Vector is designed ... ie its job as a virus is to present the new TCR ... but also silence the original
To this end, therefore, we first cloned the rearranged HLA-A*24:02-restricted and hTERT461-469-specific T-cell receptor a/ß (TCR-a/ß) genes from K3-1 and inserted them into a novel TCR gene expression vector carrying silencers for endogenous TCRs (siTCR vector)26 in redirected T cells (hTERT-siTCR vector). Notably, we used a souped-up second-generation 2A peptide-based siTCR vector that achieved an increased level of expression of the introduced TCR.27
fascinating ...